VJHemOnc is committed to improving our service to you

NCRI 2019 | CAR T-cell therapy for B-cell lymphomas: a focus on improving CR

VJHemOnc is committed to improving our service to you

Jakub Svoboda

Jakub Svoboda, MD, University of Pennsylvania, Philadelphia, PA, highlights the focus on improving CR rates in patients treated with CAR T-cell therapy as strong persistence and duration of response have already been achieved. Recorded at the 2019 National Cancer Research Institute (NCRI) Annual Cancer Conference, in Glasgow, UK.
For more information about the NCRI Cancer Conference, visit https://conference.ncri.org.uk.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter